Q-omics provides the consensus-scored WASF5P profile across patient tissues and cancer cell-line models. WASF5P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WASF5P is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, WASF5P RNA expression shows 8,728 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, BRCA, and THYM as cancer lineages where WASF5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WASF5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WASF5P survival associations across molecular data types. WASF5P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WASF5P RNA expression–survival associations across cancer types. High WASF5P expression shows unfavorable associations in ACC, THCA, DLBC, KIRP and UCEC, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for WASF5P RNA expression.
This table summarizes WASF5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for WASF5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WASF5P shows lower tumor expression in LUSC and higher tumor expression in BRCA, THCA, KIRC, PRAD and BLCA. The BRCA box plot shows higher WASF5P RNA expression in tumor versus normal tissue (log2 FC = +0.503, t-test p < 0.001).
This table shows molecular features associated with WASF5P in patient tissues and cancer cell lines. In patient samples, WASF5P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
